Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

dr. august wolff gmbh & co. kg arzneimittel - isotretinoina - cÁpsula blanda - 20 mg - isotretinoina 20 mg - isotretinoína

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

dr. august wolff gmbh & co. kg arzneimittel - isotretinoina - cÁpsula blanda - 10 mg - isotretinoina 10 mg - isotretinoína

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sun pharmaceutical industries (europe) b.v. - isotretinoina - cÁpsula blanda - 10 mg - isotretinoina 10 mg - isotretinoína

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sun pharmaceutical industries (europe) b.v. - isotretinoina - cÁpsula blanda - 20 mg - isotretinoina 20 mg - isotretinoína

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - isotrétinoïne 20 mg - capsule - 20 mg - pour une capsule > isotrétinoïne 20 mg - rétinoïdes dans le traitement de l'acné - classe pharmacothérapeutique : rétinoïdes dans le traitement de l'acné - code atc : d10ba01isotretinoine acnetrait contient de l'isotrétinoïne, qui est son principe actif. c'est un dérivé de la vitamine a, qui appartient à une classe de médicaments appelés rétinoïdes.isotretinoine acnetrait est indiqué pour le traitement des acnés sévères (telle que acné nodulaire, conglobata ou acné susceptible d'entraîner des cicatrices définitives), lorsque les traitements classiques comportant des antibiotiques par voie orale et un traitement topique n'y sont pas parvenus.le traitement par isotretinoine acnetrait doit être prescrit et surveillé par un médecin ayant une bonne expérience dans le traitement des acnés sévères. il doit connaître parfaitement les risques de ce médicament, en particulier le risque de malformations pour l'enfant à naître en cas de grossesse, et la surveillance que ce traitement impose.isotretinoine acnetrait n'est pas indiqué pour traiter les acnés survenant avant la puberté et n'est pas recommandé avant l'âge de 12 ans.

USA - engelsk - NLM (National Library of Medicine)

major pharmaceuticals - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m3 (including the m3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the pml/rarα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. tretinoin capsules are for the induction of remission only. the optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for apl after completion of induction therapy with tretinoin capsules. tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. tretinoin capsules should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin caps

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m3 (including the m3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the pml/rarα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. tretinoin capsules are for the induction of remission only. the optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for apl after completion of induction therapy with tretinoin capsules. tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. tretinoin capsules should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin capsule.

USA - engelsk - NLM (National Library of Medicine)

avkare - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (apl), french-american-british (fab) classification m3 (including the m3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the pml/rarα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. tretinoin is for the induction of remission only. the optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for apl after completion of induction therapy with tretinoin. tretinoin is contraindicated in patients with a known hypersensitivity to tretinoin, any of its components, or other retinoids.